
Please try another search
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s disease, and pediatric Crohn’s disease; and HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer. The company also develops HANSIZHUANG, a serplulimab injection to treat colorectal cancer, gastric carcinoma, and limited-stage small cell lung cancer; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat of metastatic gastroesophageal junction cancer and gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX22, HLX42, HLX43, and HLX53 to treat solid tumors; HLX11 to treat breast cancer; HLX14 to treat osteoporosis; and HLX15 for multiple myeloma. The company operates in Mainland China, the Asia Pacific, North and South America, Europe, and Oceania. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical Development Co., Ltd.
Name | Age | Since | Title |
---|---|---|---|
Ruilin Song | 61 | 2019 | Independent Non-Executive Director |
Xiaohui Guan | 54 | 2018 | Non-Executive Director |
Alberto Mantovani | - | 2023 | Member of Scientific Advisory Board |
Qiyu Chen | 53 | 2013 | Non-Executive Director |
Guoping Zhao | 76 | 2019 | Independent Non-Executive Director |
Lik Yuen Chan | 56 | 2019 | Independent Non-Executive Director |
Yifang Wu | 56 | 2015 | Non-Executive Director |
Wenjie Zhang | 58 | 2019 | Non-Executive Chairman of the Board |
Tak Young So | 54 | 2019 | Independent Non-Executive Director |
David R. Gandara | 77 | 2023 | Member of Scientific Advisory Board |
Jun Zhu | 46 | 2021 | CEO & Executive Director |
Deyong Wen | 54 | 2022 | Non-Executive Director |
Rongli Feng | 50 | 2020 | Chairman of Supervisory Board |
K. Christopher Garcia | - | 2023 | Member of Scientific Advisory Board |
Xingli Wang | 61 | 2023 | Non-Executive Director |
Yangxin Fu | - | - | Member of Scientific Advisory Board |
Lixin Zhang | - | - | Member of Scientific Advisory Board |
Zhiyong Liu | 52 | 2025 | GM of Production & Employee Representative Supervisor |
Deli Kong | 50 | 2016 | Supervisor |
Jun Wang | - | 2025 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review